| | 914088-09-8 Basic information More.. |
| Product Name: | Brentuximab | | Synonyms: | Brentuximab;Brentuximab Vedotin;Moxetumomab;Anti-CLDN18.2;Anti NS1 of dengue virus;Research Grade Brentuximab(DHD80901);Adcetris;cAC10-vcMMAE | | CAS: | 914088-09-8 | | MF: | | | MW: | 0 | | EINECS: | | | Mol File: | Mol File |  |
Use
Brentuximab verdotin was approved by the U.S. FDA in August 2011
for treatment of Hodgkin’s lymphoma (HL) in patients who have failed autologous stem cell transplant (ASCT) or ASCT ineligible patients who have
failed at least two prior chemotherapy regimens, and for second line treatment of systemic anaplastic large cell leukemia (ALCL).
Brentuximab verdotin is a chimeric (mouse V region/human
C region) CD30 binding monoclonal antibody (cAC10) that is
conjugated via cysteine residues to a small molecule comprising a cysteine
reactive dipeptide linker moiety and the microtubule polymerization
inhibitor monomethyl auristatin E(MMAE). The antibody component
of the drug binds to CD30 expressing tumor cells, and the active
cytotoxic component, MMAE, is released by proteolytic cleavage of the
dipeptide linker moiety.
- Brentuximab vedotin
-
- US $979.00-1960.00 / mg
- 2025-07-09
- CAS:914088-09-8
- Min. Order:
- Purity: 97.73% (SEC-HPLC)
- Supply Ability: 10g
|
|
914088-09-8
Recommend Suppliers |
|